Gao Ming, Liu Liying, Li Shenglei, Zhang Xudong, Chang Zhiwei, Zhang Mingzhi
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Department of Oncology, The First People's Hospital of Zhengzhou, Zhengzhou, Henan 450004, P.R. China.
Oncol Rep. 2015 Nov;34(5):2523-32. doi: 10.3892/or.2015.4261. Epub 2015 Sep 9.
In the present study, we evaluated the mechanisms of CDC42 in association with the microRNA-137 (miR-137)-induced inhibition of human hepatocellular carcinoma (HCC). The gene expression levels of miR-137 were evaluated in HCC cell lines. Direct association of miR-137 with its downstream target, cell division control protein 42 (CDC42), was evaluated by dual-luciferase assay, western blot analysis and correlation analysis using clinical tumor samples. In the HCC HuH7 and MHCC97L cell lines, miR-137 was upregulated to inhibit cell proliferation and metastasis in vitro and tumor growth in vivo. CDC42 was overexpressed in the HuH7 and MHCC97L cells to evaluate its effect on the miR-137-mediated antitumor effects. Furthermore, possible crosstalk between CDC42 and another miR-137 target gene, AKT2, was evaluated by co-overexpressing CDC42 and AKT2 in the HuH7 and MHCC97L cells and examining their effects on miR-137-mediated HCC regulation. miR-137 was confirmed to be downregulated in the HCC cell lines. Dual‑luciferase assay showed that CDC42 was directly targeted by miR-137, and western blotting showed that CDC42 was downregulated by miR-137 upregulation in the HuH7 and MHCC97L cells. In human tumors, the expression levels of CDC42 and miR-137 were inversely correlated. The inhibitory effects of miR-137 on HCC proliferation, metastasis and in vivo tumor growth were all ameliorated by CDC42 overexpression. Furthermore, co-overexpression of AKT2 in addition to CDC42 additively reduced the inhibition of miR-137 on HCC proliferation and metastasis, suggesting two independent pathways of CDC42 and AKT2 in miR-137-mediated HCC regulation. Our study demonstrated that CDC42 independently regulated the antitumor effects of miR-137 in human HCC.
在本研究中,我们评估了细胞分裂周期蛋白42(CDC42)与微小RNA-137(miR-137)诱导的人肝细胞癌(HCC)抑制作用相关的机制。在肝癌细胞系中评估了miR-137的基因表达水平。通过双荧光素酶报告基因检测、蛋白质印迹分析以及使用临床肿瘤样本的相关性分析,评估了miR-137与其下游靶标细胞分裂控制蛋白42(CDC42)的直接关联。在肝癌HuH7和MHCC97L细胞系中,上调miR-137可在体外抑制细胞增殖和转移,并在体内抑制肿瘤生长。在HuH7和MHCC97L细胞中过表达CDC42,以评估其对miR-137介导的抗肿瘤作用的影响。此外,通过在HuH7和MHCC97L细胞中共过表达CDC42和AKT2,并检测它们对miR-137介导的肝癌调控的影响,评估了CDC42与另一个miR-137靶标基因AKT2之间可能存在的相互作用。证实miR-137在肝癌细胞系中表达下调。双荧光素酶报告基因检测表明CDC42是miR-137的直接靶标,蛋白质印迹显示在HuH7和MHCC97L细胞中,上调miR-137可使CDC42表达下调。在人类肿瘤中,CDC42和miR-137的表达水平呈负相关。过表达CDC42可改善miR-137对肝癌增殖、转移及体内肿瘤生长的抑制作用。此外,除了CDC42外,共过表达AKT2可累加性地降低miR-137对肝癌增殖和转移的抑制作用,提示在miR-137介导的肝癌调控中,CDC42和AKT2存在两条独立的途径。我们的研究表明,CDC42独立调节miR-137在人类肝癌中的抗肿瘤作用。